Radioimmunotherapy of malignancy using antibody targeted radionuclides.
Antibodies directed against tumour associated antigens provide a means for delivering preferentially cytotoxic radionuclides to the cells of primary and secondary tumours. The factors that influence the effectiveness of the radiation in the tumour compared with its effect on the radiosensitive normal tissues include the specificity of the antibody, the distribution of targeted energy within the tumour and the host's response to the injected foreign antibody. Recently some encouraging results from clinical trials of radioimmunotherapy have been reported in the literature. There is a continual search for more avid and specific antibodies, and the techniques of genetic engineering are being applied to the problem of reducing the antigenicity and mass of the carrier antibody. The improved efficiency of the labelled antibody needs to be supplemented by an identification of those tumours most likely to respond to this form of therapy.
D000818:Animals; D000906:Antibodies; D000951:Antigens, Neoplasm / Q000276:immunology; D001666:Binding Sites, Antibody; D004273:DNA, Neoplasm; D006801:Humans; D007128:Immunoglobulin Fragments; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D009369:Neoplasms / Q000532:radiotherapy*; D011868:Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*
D000906:Antibodies; D000951:Antigens, Neoplasm; D004273:DNA, Neoplasm; D007128:Immunoglobulin Fragments; D007457:Iodine Radioisotopes; D011868:Radioisotopes